Loading
A phase 2 trial of Mirvetuximab soravtansine in ovarian cancer, run by AbbVie, now recruiting.
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine is a phase 2 interventional study registered as NCT06682988 by AbbVie, with 110 participants planned, started 2025-05-28 and due to reach its primary completion in 2026-07. Interventions recorded: Mirvetuximab Soravtansine. Conditions listed: Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancers. No results are recorded here; the registry entry is the source.
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Mirvetuximab soravtansine, Platinum-resistant ovarian cancer, AbbVie (incl. ImmunoGen, Capstan), Antibody-drug conjugate (ADC).
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Mirvetuximab soravtansine, Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Platinum-resistant ovarian cancer, Antibody-drug conjugate (ADC), Ovarian cancer.